Michael S. Beaubaire

• The CEO of an emerging early-stage biotechnology company focused on developing breakthrough therapies in cardiovascular disease.
• Developing and implementing strategic plans to progress platform assets towards clinical trials and critical milestone inflection.
• Leading capital strategy with investor and partner community to secure capital and oversee grant solicitations to support drug development pathway.
• Our initial indication is the unmet need in Diastolic Heart Failure with a potential new class of drugs targeting the myosin-actin signaling.
• Exploring companion bio-marker diagnostic and expansion into arrythmia disease.

• Provided executive, strategic, and capital advisory services to support company growth and achieve key milestones in the emerging local life sciences community.
• Advised portfolio of Rosalind Franklin University School of Medicine technology opportunities and mentored U of C integrated sensing medical device startup to enhance commercialization potential.
• Mentored scientists and students on business organization and regulatory steps to advance opportunities into clinical trials.

• Provided strategic, business licensing, and capital services to emerging technology companies in health sciences, IT, and AI at Clearspan.
• Leveraged scientific, capital, and operating experience to advise clients on M&A, business development, and capital structure at Clearspan.
• Developed accretive strategies for clients, ranging from startups to established companies, to promote growth and development.

Created a life science and healthcare advisory group focusing on investment and portfolio management, business development, strategic consulting, and capital raising services for equity funds, consulting organizations, and start-ups.

• Advised CoreIR clients as Principal Healthcare advisor to enhance strategic decision-making.
• Guided health science clients in navigating public and private investor markets, developing profiles to support successful execution of strategic initiatives.
• Leveraged extensive healthcare experience and capital markets expertise to support emerging companies in advancing innovative technologies and delivering investor returns.
• Conducted Health Science Advisory Services, drove New Business Development, managed relationships, and developed Partnering Strategies.

• Identified and engaged partners targeting systemic chronic conditions associated with aging to advance new combination therapies into clinical trials.
• Developed strategic alliances with gene therapy companies to enhance collaborative opportunities.
• Developed corporate strategies and assisted in capital planning to position the company for success.
• Coordinated market strategy with key influencers through one-on-one meetings and participation in relevant business and scientific conferences.
• Acted as Chief Medical Officer to strengthen relationships within the business and scientific community.

• Oversaw organizational leadership as acting chief executive officer and director during 2020-2021.
• Led Northwestern University biotechnology spinout to develop breakthrough therapies for COVID-19 and kidney disease.
• Developed and implemented strategic plan to advance platform assets toward clinical trials and achieve critical milestones.
• Led interactions with investors and partners to secure capital investment and grant solicitations.
• Engaged with intellectual property, manufacturing, and clinical research teams to support development initiatives.

• Advisor and board member to pre-clinical orphan drug company focusing on treating multiple types of Gaucher’s Disease with additional signal activity in Cystic Fibrosis.
• Developed capital strategy to advance IND activity for clinical trial entry and establish monetization alliance for lifesaving therapeutic technology.
• Coordinated recruitment of CEO and board member, enhancing leadership team through candidate assessment and interview facilitation.

• Provided operating and financial advisory services to fast-growth and emerging technology clients in technology, biotechnology, and device sectors globally.
• Delivered tailored solutions for clients in biotechnology, medical device, and digital health sectors, addressing specific client needs.
• Leveraged scientific, capital, and operating experience to develop growth strategies and enhance capital market development for NGA.

• Founded and scaled organization to develop breakthrough therapies targeting immune responses in oncology and serious infectious diseases.
• Collaborated with Venture Capital, institutional investors, and high net worth individuals to align manufacturing partners, academic research alliances, and potential commercial collaborators.
• Utilized technology and IP from Stanford University to develop adjunctive and single-agent therapeutics for cancer and epidemic infections.

• Committed over $1B to emerging health science companies with >$300M actively invested.
• Oversaw and evaluated life science private company opportunities to expand fund investing activity and enhance long-term returns.
• Provided insights on investing thesis in public health science companies by collaborating with team and scientific board members to assess market and clinical standing.
• Triangulate the inherent market value of the companies, the underlying capital requirements for progress and the foundational technology/executives to drive investment opportunities which supports the firm’s fundamental investing strategy.
• To support this fundamental-only investing approach, the decision process intersects understanding the competitive landscape, creating widespread management relationships and processing regulatory timelines/challenges to achieve accretive market returns.

• Collaborated with cross-border clients to develop business and strategic plans for in-licensing and out-licensing assets, enhancing market entry opportunities.
• Facilitated capital raising for Ocularis, a company focused on developing therapies for night vision challenges, strengthening financial backing for product advancement.
• Enabled partnering introductions for the company, fostering strategic alliances and enhancing collaboration opportunities.
• Primary focus on small North American biotechnology companies to collaborate with Far East, particularly Japan and South Korea.
• Worked with capital strategies for client companies with venture capital, family offices and angel networks in the US.

• Developed Diabetes sector vertical and authored market overview white paper to capture clinical and strategic leadership perspectives for advising emerging companies in this disease state.
• Developed strategic recommendations based on market analysis and client insights.
• Partnered with merchant bank to advise healthcare industry on strategic and transaction activities, including developmental stage companies, commercialization activities, and LBO bids.
• Led client workshops to gather requirements and assess business needs.
• Facilitated cross-functional team collaboration to implement project solutions.

• Managed projects raising $5 to $100 million in private equity investments and $5 to $30 million in merger & acquisition transactions, driving successful outcomes.
• Executed equity capital financing for early-stage specialty hospital operator and financing facility for roll-up in home healthcare sector by identifying operational, reimbursement, and core competency issues.
• Leveraged medical science knowledge, operational experience, and strategic financial training to advise healthcare clients on investment opportunities.
• Specific engagement experience in broad-based healthcare delivery, innovative medical devices, specialty biopharmaceutical discovery and disease management companies.
• Key deal and origination team member of a boutique investment-banking firm focused on capital raising and mergers & acquisitions in the healthcare industry.

• Increased revenue 35% with a corresponding 40% boost to patient membership while decreasing administrative cost structure in excess of 40% through patient and payor recruitment, implementation of e-information technology systems for improved utilization management, and improved managed care contracting.
• Managed independent physician association of over 300 doctors and led PHO, developing partnerships with providers and hospital to deliver integrated care in a quality and cost-effective environment.
• Restructured organization to strengthen financial foundation, enhance operational efficiencies, and improve responsiveness to partners.
• Launched pilot electronic referral network technology and electronic medical chart interface to streamline processes.

• Engaged in deals ranging from $80 million to $1.2 billion in scope.
• Created and managed financial modeling analysis to identify alternatives for enhancing company strengths.
• Analyzed mergers, acquisitions, and capital equity alternatives as a member of a team serving corporate clients.
• Project focus was on health care, chemical and pharmaceutical entities.